- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06785376
P3 Trial: Estimating the Impact of a Multilevel, Multicomponent Intervention to Increase Uptake of HIV Testing and Biomedical HIV Prevention Among African-American/Black Gay, Bisexual, and Same-gender Loving Men (P3)
Estimating the Impact of a Multilevel, Multicomponent Intervention to Increase Uptake of HIV Testing and Biomedical HIV Prevention Among African-American/Black Gay, Bisexual and Same-gender Loving Men
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The major goal of this study is to evaluate a multi-component, multilevel HIV prevention intervention that targets theoretically-informed and empirically-identified barriers to and facilitators of both HIV testing and PEP/PrEP uptake by combining existing evidence-based and novel evidence-informed components and integrating them into a community-based organization's (CBO) standard of care (SOC) PEP/PrEP navigation program. The existing evidence-based, individual-level component is TRUST (R01 DA-038108), a single-session peer-based HIV self-testing intervention for Black MSM. The existing, evidence-based community-level component is a social/print media campaign (CHHANGE [R21 MH-102182-01] & PEPTALK [R21 AI-122996]) to reduce community-level HIV stigma and drive demand for HIV testing, PEP and PrEP. The novel, evidence-informed, individual-level component is "Do It Yourself (DIY)", a 3-session enhancement of the CBO SOC peer navigation program that promotes empowerment, autonomy, stigma coping/resistance and social support via a novel "sexual self-care in-a-box" and peer-to-peer training to increase HIV testing and PEP/PrEP uptake.
The Specific Aims are:
- Component test DIY, adapt social/print media campaign & manualize full intervention. We will conduct modified intervention mapping, component testing and post-test interviews with 20 PrEP-eligible Black MSM (for DIY) and focus groups with 20 PrEP-eligible Black MSM (for media campaign adaptation). A 15-person community consulting group of Black MSM, community leaders, media professionals, and service providers, will provide feedback on both components and the full manualized intervention.
Estimate main and interactive effects of components on recent HIV testing and PEP/PrEP uptake.
H1: Exposure to TRUST, DIY, and the media campaign will each be associated with (1) higher past 3-month HIV testing; and (2) shorter time to PrEP uptake over time.
H2: A multiplicative interaction among TRUST, DIY and length of exposure to the media campaign will emerge, such that exposure to combination of multiple interventions will be associated with the more positive outcomes compared to the impact of each intervention component individually.
Primary outcomes: (1) HIV testing in past 3 months; (2) time to PrEP uptake: assessed via self-report, medical record, urine test (UrSure, qualitative, visually-read point of care test [validated machine analysis] measuring adherence to tenofovir, metabolite of tenofovir disopropil fumarate (TDF) and tenofovir alafenamide (TAF) via lateral flow immunoassay). Secondary outcomes:
consistent HIV testing (2+ tests 3 months apart in 9 months), PEP uptake (self-report, medical record), PrEP/PEP adherence (self-report/ medical record/urine test). To test hypotheses, we will use a 2x2 factorial design to randomize and follow for 18 months 480 PrEP-eligible Black MSM (aged 18-65) living in NYC to one of four combinations: 1) SOC, DIY & TRUST; 2) SOC & TRUST (no DIY); 3) SOC & DIY (no TRUST); 4) SOC ALONE (no TRUST and no DIY). Hypotheses will be tested via regression (GEE) and Cox proportional hazard models; impact of the social/media campaign, delivered to both geographic (print media) and Black MSM communities (social media) and launched midway through recruitment, will be assessed through assessment of timing and length of exposure as covariates in the regression models and through interrupted time series methods.
- Describe the feasibility, acceptability, and usability of intervention components and package via the Re-AIM implementation framework with an emphasis on component implementation by a CBO program.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Victoria Frye, MPH, DrPH
- Phone Number: 2128534490
- Email: vaf5@columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10027
- Recruiting
- Columbia University
-
Contact:
- Victoria Frye, MPH, DrPH
- Phone Number: 2128534490
- Email: vaf5@columbia.edu
-
Contact:
- Victoria Frye, MPH, DrPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- assigned biological male sex at birth;
- 18-65 years of age;
- self-identify as: Black, African-American, Afro-Caribbean, Black African, Afro-Latino or multiethnic Black;
- reside in the NYC metro area; (5) not HIV-positive (tested before randomization);
6) report insertive or receptive anal intercourse with another man in the past six months; 7) not currently on PEP or PrEP; 8) communicate in English or Spanish; 9) provide informed consent for the study.
Exclusion Criteria:
- Sexual identity is not an exclusion criterion
- potential participants who self-identify as Latino must also identify as Black (as per above) to be included
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: A. SOC
A. standard of care single-session, low threshold peer/near-peer navigation to PrEP.
|
standard of care single-session, low threshold peer/near-peer navigation to PrEP.
|
|
Experimental: B. SOC & TRUST
B. SOC standard of care single-session, low threshold peer/near-peer navigation to PrEP; TRUST single-session HIV self-testing training with facilitator
|
standard of care single-session, low threshold peer/near-peer navigation to PrEP.
TRUST is a single-session HIV self-testing training with facilitator
|
|
Experimental: C. SOC & DIY
C. SOC standard of care single-session, low threshold peer/near-peer navigation to PrEP; DIY three-session sexual health promotion/HIV prevention training with facilitator
|
standard of care single-session, low threshold peer/near-peer navigation to PrEP.
DIY is 3-session program that promotes empowerment, autonomy, stigma coping/resistance and social support to promote sexual health and pleasure and HIV prevention.
|
|
Experimental: D. SOC, TRUST & DIY
D. SOC standard of care single-session, low threshold peer/near-peer navigation to PrEP; TRUST single-session HIV self-testing training with facilitator; DIY three-session sexual health promotion/HIV prevention training with facilitator
|
standard of care single-session, low threshold peer/near-peer navigation to PrEP.
TRUST is a single-session HIV self-testing training with facilitator
DIY is 3-session program that promotes empowerment, autonomy, stigma coping/resistance and social support to promote sexual health and pleasure and HIV prevention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
P3M HIV testing
Time Frame: past 3 months
|
did the participant engage in HIV testing in the past 3 months
|
past 3 months
|
|
PrEP uptake
Time Frame: past 3 months
|
PrEP uptake (yes/no)/time to PrEP uptake (assessed via self-report, medical record)
|
past 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
consistent HIV testing
Time Frame: over 9 months
|
consistent HIV testing (2+ tests 3 months apart in 9 months)
|
over 9 months
|
|
PEP uptake
Time Frame: past 3 months
|
PEP uptake (self-report, medical record)
|
past 3 months
|
|
PrEP and PEP adherence
Time Frame: past 3 months
|
PrEP/PEP adherence (self-report/medical record)
|
past 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- AAAU8754
- R01MH129198 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Testing
-
Universidad Peruana Cayetano HerediaCompleted
-
New York UniversityCompletedHIV TestingUnited States
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
State University of New York at BuffaloYale University Center for Interdisciplinary Research on AIDSNot yet recruitingHIV Prevention | HIV Testing | Sexual and Reproductive HealthUnited States
-
New York Blood CenterTerminated
-
University of South CarolinaDuke University; Kilimanjaro Christian Medical Centre, TanzaniaCompletedHIV TestingUnited States, Tanzania
-
Universidad Peruana Cayetano HerediaNational Institutes of Health (NIH); NGO Via LibreCompleted
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
Catholic Relief ServicesCenters for Disease Control and PreventionCompleted
Clinical Trials on SOC
-
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.Not yet recruitingSystemic Lupus Erythematosus
-
Applied Biologics, LLCSerenaGroup, Inc.RecruitingDiabetic Foot | Foot Ulcer | Diabetic Foot Ulcer | Ulcer Foot | DFUUnited States
-
Five Eleven Pharma, Inc.Indiana UniversityRecruiting
-
Corvus Pharmaceuticals, Inc.TerminatedCovid-19United States, Colombia, Spain, Canada, Peru, Brazil, Italy, Argentina, Chile, Germany, Mexico, Ukraine
-
KLOX Technologies Inc.Unknown
-
Boehringer IngelheimCompletedHepatitis C, ChronicFrance, Germany, Switzerland
-
FibroBiologicsNot yet recruiting
-
BlueSphere Bio, IncRecruitingAML, Adult Recurrent | AML - Acute Myeloid Leukemia | AML With Mutated NPM1United States
-
The University of Texas Medical Branch, GalvestonUniversity of Texas Southwestern Medical Center; United States Army Institute... and other collaboratorsCompletedMuscle Weakness | Muscle; Fatigue, Heart | Late Effect of Burn | Burn RehabilitationUnited States
-
National Taiwan University HospitalMinistry of Science and Technology, TaiwanCompletedEndotracheal Intubation | Oropharyngeal Dysphagia | Randomized Controlled Trial | Swallowing DisorderTaiwan